Molecular Imaging Study on In Vivo Distribution and Pharmacokinetics of Modified Small Interfering RNAs (siRNAs)
Molecular imaging was used to study the biodistribution, pharmacokinetics, and activity of naked small interfering RNAs (siRNAs). siRNAs with riboses chemically modified in the 2′ position were compared with unmodified siRNA. In vitro , replacement of the 2′-hydroxyl (2′OH) group of certain nucleoti...
Gespeichert in:
Veröffentlicht in: | Oligonucleotides 2008-09, Vol.18 (3), p.21-212 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Molecular imaging was used to study the biodistribution, pharmacokinetics, and activity of naked small interfering RNAs (siRNAs). siRNAs with riboses chemically modified in the 2′ position were compared with unmodified siRNA.
In vitro
, replacement of the 2′-hydroxyl (2′OH) group of certain nucleotides in an siRNA sequence by a fluorine atom (2′F) on both antisense (AS) and sense (S) strands [2′F(AS/S)], or by a methoxy group (2′OMe) on the S strand [2′OH(AS)/2′OMe(S)], was compatible with RNA interference. Different siRNAs [2′F(AS/S), 2′OH(AS)/2′OMe(S), and 2′OH(AS/S)] were labeled with fluorine-18 (conjugation with [
18
F]FPyBrA), and comparative dynamic and quantitative imaging was performed with positron emission tomography. After intravenous injections of [
18
F]siRNAs in rodents, total radioactivity was rapidly eliminated by the kidneys and the liver. Tissue distribution of the different siRNAs were similar, and their bioavailability (as judged from blood persistence and stability) increased in the order 2′OH(AS/S) = 2′OH(AS)/2′OMe(S) < 2′F(AS/S). However, in our
in vivo
model, the 2′F(AS/S) siRNA, despite its higher bioavailability, was not able to induce a higher interference effect with respect to the 2′OH(AS/S) siRNA. Molecular imaging approaches, applied in the present work to both natural and chemically modified siRNAs, can contribute to the development of these macromolecules as therapeutic agents. |
---|---|
ISSN: | 1545-4576 2159-3337 1557-8526 2159-3345 |
DOI: | 10.1089/oli.2008.0133 |